Has Mary McLaughlin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $51,473 in general payments to Mary McLaughlin, MD across 19 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary McLaughlin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary McLaughlin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary McLaughlin, MD

Cardiovascular Disease · New York, NYNPI 1568463867

Payments from drug & device makers

$51,473in general payments, 2019–2025

Across 19 payments — averaging $2709.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$36K
Astrazeneca UK Limited$15K
Abbott$150
Angiodynamics, Inc.$117
E.r. Squibb & Sons, L.L.C.$35
Irhythm Technologies, Inc.$18
plus $16 from 1 others

What the payments were for

Food & beverage$336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	6	$36,254
Astrazeneca UK Limited	6	$14,883
Abbott	1	$150
Angiodynamics, Inc.	3	$117
E.r. Squibb & Sons, L.L.C.	1	$35
Irhythm Technologies, Inc.	1	$18
Novo Nordisk	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MitraClip$150

How this compares

$51,473 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$85,355

Medicare patients

670

Services billed

1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	35	$33,473
EntrestoSacubitril/Valsartan	14	$9,245
Nitroglycerin PatchNitroglycerin	17	$648
Rosuvastatin Calcium	45	$612
Metoprolol Succinate	37	$412
Atorvastatin Calcium	28	$333
Propranolol Hcl	14	$238
Amlodipine Besylate	37	$190
Isosorbide Mononitrate ErIsosorbide Mononitrate	16	$139
Carvedilol	15	$128
Losartan Potassium	20	$106
Atenolol	11	$69

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

James MinNew York$41.1M
Robert RosensonNew York$6.9M
Roxana MehranNew York$6.4M
Roger HajjarNew York$5.2M
Philippe GenereuxNew York$4.4M
Gregg StoneNew York$3.7M
Valentin FusterNew York$2.9M
Tamim NazifNew York$2.2M
Howard WeintraubNew York$1.7M
Anuradha Lala-TrindadeNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →